G.H. Blijham

5.7k total citations
88 papers, 4.6k citations indexed

About

G.H. Blijham is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, G.H. Blijham has authored 88 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in G.H. Blijham's work include Cancer Treatment and Pharmacology (16 papers), Colorectal Cancer Treatments and Studies (15 papers) and Gastric Cancer Management and Outcomes (12 papers). G.H. Blijham is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Colorectal Cancer Treatments and Studies (15 papers) and Gastric Cancer Management and Outcomes (12 papers). G.H. Blijham collaborates with scholars based in Netherlands, Belgium and Germany. G.H. Blijham's co-authors include B. Schütte, M. Reynders, Fred T. Bosman, Gerard Groenewegen, G.J. Hordijk, Wynand J.G. Ros, J.R.J. de Leeuw, J.A.M. Winnubst, Alexander de Graeff and Harry Bleiberg and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

G.H. Blijham

83 papers receiving 4.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G.H. Blijham Netherlands 35 2.3k 1.2k 1.1k 1.0k 738 88 4.6k
Walter G. Gunn United States 17 1.9k 0.8× 1.4k 1.2× 806 0.8× 985 1.0× 465 0.6× 45 4.5k
T. S. Squires United States 8 1.5k 0.7× 1.3k 1.1× 797 0.8× 798 0.8× 487 0.7× 8 3.8k
Pere Gascón Spain 39 3.0k 1.3× 1.0k 0.9× 1.2k 1.1× 747 0.7× 613 0.8× 163 5.8k
Vincenzo Tombolini Italy 36 1.5k 0.6× 1.4k 1.2× 1.1k 1.0× 953 0.9× 515 0.7× 224 4.4k
Heather Lin United States 40 2.2k 0.9× 1.6k 1.3× 1.3k 1.2× 949 0.9× 1.0k 1.4× 173 4.9k
Gloria Broadwater United States 42 3.1k 1.3× 1.0k 0.8× 1.2k 1.1× 776 0.8× 1.8k 2.4× 182 6.2k
Nicolas Magné France 43 2.2k 0.9× 2.1k 1.7× 1.1k 1.0× 1.2k 1.2× 984 1.3× 318 6.1k
Noriyuki Katsumata Japan 38 2.8k 1.2× 811 0.7× 776 0.7× 1.2k 1.2× 708 1.0× 183 5.7k
Carol J. Etzel United States 37 993 0.4× 1.1k 0.9× 1.4k 1.3× 664 0.7× 791 1.1× 128 4.6k
Francisco Vera-Badillo Canada 27 3.4k 1.4× 1.6k 1.4× 754 0.7× 902 0.9× 1.2k 1.7× 76 5.5k

Countries citing papers authored by G.H. Blijham

Since Specialization
Citations

This map shows the geographic impact of G.H. Blijham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G.H. Blijham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G.H. Blijham more than expected).

Fields of papers citing papers by G.H. Blijham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G.H. Blijham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G.H. Blijham. The network helps show where G.H. Blijham may publish in the future.

Co-authorship network of co-authors of G.H. Blijham

This figure shows the co-authorship network connecting the top 25 collaborators of G.H. Blijham. A scholar is included among the top collaborators of G.H. Blijham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G.H. Blijham. G.H. Blijham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lalisang, Roy, Frans Erdkamp, C. J. Rodenburg, et al.. (2011). Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. Breast Cancer Research and Treatment. 128(2). 437–445. 5 indexed citations
2.
3.
Repp, Roland, Heidi H. van Ojik, Thomas Valerius, et al.. (2003). Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. British Journal of Cancer. 89(12). 2234–2243. 62 indexed citations
4.
Köhne, C.-H., David Cunningham, Francesco Di Costanzo, et al.. (2002). Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Annals of Oncology. 13(2). 308–317. 356 indexed citations
5.
6.
Zonnenberg, Bernard A., et al.. (2000). Radioimmunodiagnosis and therapy. Cancer Treatment Reviews. 26(1). 3–10. 14 indexed citations
7.
Hillen, H.F.P., Harry C. Schouten, Roy Lalisang, et al.. (2000). True. British Journal of Cancer. 82(12). 1914–1919. 5 indexed citations
8.
Graeff, Alexander de, J.R.J. de Leeuw, Wynand J.G. Ros, et al.. (1999). A prospective study on quality of life of patients with cancer of the oral cavity or oropharynx treated with surgery with or without radiotherapy. Oral Oncology. 35(1). 27–32. 142 indexed citations
9.
Blijham, G.H., et al.. (1998). CLINICAL RESEARCH ON ANTIANGIOGENIC THERAPY. Pharmacological Research. 37(1). 1–16. 34 indexed citations
10.
11.
Blijham, G.H.. (1997). Should patients with advanced colorectal cancer be treated with chemotherapy?. European Journal of Cancer. 33(6). 815–817. 7 indexed citations
12.
Vries, Elisabeth G.E. de, Sjoerd Rodenhuis, H. Schouten, et al.. (1996). Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer. Breast Cancer Research and Treatment. 39(3). 307–313. 14 indexed citations
13.
Lips, Cornelis J.M., Rudy M. Landsvater, Jo W.M. Höppener, et al.. (1995). From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family*. Journal of Internal Medicine. 238(4). 347–356. 16 indexed citations
14.
Piedbois, Pascal, Marc Buyse, G.H. Blijham, et al.. (1994). Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Journal of Clinical Oncology. 12(5). 960–969. 162 indexed citations
15.
Schütte, B., et al.. (1993). Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling. British Journal of Cancer. 67(6). 1217–1222. 35 indexed citations
16.
Blijham, G.H.. (1991). Chemotherapy of colorectal cancer. Anti-Cancer Drugs. 2(3). 233–246. 33 indexed citations
17.
Velde, G.P.M. ten, et al.. (1987). Cisplatin and cytarabine combination chemotherapy of advanced non-small cell lung cancer: A pilot study. European Journal of Cancer and Clinical Oncology. 23(5). 581–582. 1 indexed citations
18.
Bijvoet, O. L. M., J. Hermans, H.I.J. Harinck, et al.. (1987). REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT. The Lancet. 330(8566). 983–985. 162 indexed citations
19.
Velde, G.P.M. ten, et al.. (1986). Alternating Chemotherapy, Prophylactic Cranial Irradiation and Late Local Thoracic Irradiation for Small-Cell Lung Cancer. Respiration. 49(3). 216–221. 1 indexed citations
20.
Blijham, G.H., et al.. (1985). Primary chemotherapy in cancer medicine. OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information). 142(6). 1077–80. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Walter G. Gunn Breakdown of academic impact, for papers by T. S. Squires Breakdown of academic impact, for papers by Pere Gascón Breakdown of academic impact, for papers by Vincenzo Tombolini Breakdown of academic impact, for papers by Heather Lin Breakdown of academic impact, for papers by Gloria Broadwater Breakdown of academic impact, for papers by Nicolas Magné Breakdown of academic impact, for papers by Noriyuki Katsumata Breakdown of academic impact, for papers by Carol J. Etzel Breakdown of academic impact, for papers by Francisco Vera-Badillo
Rankless by CCL
2026